Alerts will be sent to your verified email
Verify Email
EMMESSA
|
Emmessar Biotech&Nut
|
Beryl Drugs
|
Parmax Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
13.7 % | 2.54 % | -1624.87 % |
|
5yr Avg Net Profit Margin
|
71.53 % | 0.66 % | -9.48 % |
|
Price to Book
|
1.82 | 1.37 | 0.0 |
|
P/E
|
34.15 | 58.69 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
68.18 Days | -619.24 Days | -161.05 Days |
|
5yr Average Interest Coverage Ratio
|
815.2 | 1.68 | 1.16 |
|
5yr Avg ROCE
|
19.97 % | 5.73 % | -9.94 % |
|
5yr Avg Operating Profit Margin
|
-101.39 % | 7.19 % | 3.93 % |
|
5 yr average Debt to Equity
|
0.0 | 0.64 | 17.42 |
|
5yr CAGR Net Profit
|
0.0 | 72.78 % | n/a |
|
5yr Average Return on Assets
|
10.86 % | 1.31 % | -6.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
59.53 % | 26.38 % | 30.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.34 % | 1.46 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Emmessar Biotech&Nut
|
Beryl Drugs
|
Parmax Pharma
|
|---|